About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Investor Centre
- Investor Centre
- News & ASX Announcements
Contact

Hit enter to search or ESC to close

Retirement of Non-Executive Director

May 19, 2016

Click here to read more

Post navigation

Phosphagenics Expands License Agreement for Diclofenac Gel

2016 May 19 AGM Chairman and CEO Addresses

Related Posts

Receipt of R&D Tax Incentive

November 27, 2018

Apppointment of Consultant to Assist in Commercialising TPM for the Mass Market

June 9, 2015

Phosphagenics Announces Equity Raising

September 26, 2017

Recent Posts

Avecho investor update – webinar recording
June 25, 2020
Ashland Purchases Manufacturing Rights for VitalET and TPM
June 20, 2019
Change of Company Name and ASX Code
May 24, 2019

Categories

Analyst Coverage
Company Announcement
Company Report
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- News & ASX Announcements

© Copyright 2019 Avecho Biotechnology Ltd.